Lovastatin — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Hyperlipidemia

• Atorvastatin
• Ezetimibe
• Fenofibrate
• Gemfibrozil
• Pravastatin
• Rosuvastatin
• Simvastatin

Other medications in Heart & Cardiovascular

• Macitentan
• Metolazone
• Metoprolol
• Metoprolol Succinate
• Milrinone
• Moexipril
• Nadolol
• Nebivolol

What Lovastatin is approved for (FDA label)

Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk.

Source: Read the full FDA label on DailyMed. Label effective date: July 23, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Lovastatin (FDA label)

Adverse Reactions Phase III Clinical Studies In Phase III controlled clinical studies involving 613 patients treated with lovastatin, the adverse experience profile was similar to that shown below for the 8,245-patient EXCEL study (see Expanded Clinical Evaluation of Lovastatin [EXCEL] Study ). Persistent increases of serum transaminases have been noted (see WARNINGS , Liver Dysfunction ). About 11% of patients had elevations of CK levels of at least twice the normal value on one or more occasions. The corresponding values for the control agent cholestyramine was 9 percent. This was attributable to the noncardiac fraction of CK. Large increases in CK have sometimes been reported (see WARNINGS , Myopathy/Rhabdomyolysis ).

Source: FDA prescribing information (DailyMed). Set ID: 9438d8a0-ca5b-4676-aab9-d0241ccff6c9. SPL document ID: 574beb60-70f7-dfa0-e063-6394a90aa90d. Label effective date: July 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Lovastatin (FDA label)

Hypersensitivity to any component of this medication. Active liver disease or unexplained persistent elevations of serum transaminases (see WARNINGS ). Concomitant administration with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin ,nefazodone, and cobicistat-containing products) (see WARNINGS , Myopathy/Rhabdomyolysis ) . Pregnancy and lactation. ( see PRECAUTIONS, Pregnancy and Nursing Mothers ). Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. Because of the ability of inhibitors of HMG-CoA reductase such as lovastatin to decrease the synthesis of cholesterol and possibly other products of the cholesterol biosynthesis pathway, lovastatin is contraindicated during pregnancy and in nursing mothers.

Source: FDA prescribing information (DailyMed). Set ID: 9438d8a0-ca5b-4676-aab9-d0241ccff6c9. SPL document ID: 574beb60-70f7-dfa0-e063-6394a90aa90d. Label effective date: July 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Lovastatin (FDA label)

CYP3A4 Interactions Lovastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Strong inhibitors of CYP3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, erythromycin, and cobicistat-containing products), and grapefruit juice increase the risk of myopathy by reducing the elimination of lovastatin. (See CONTRAINDICATIONS , WARNINGS, Myopathy/Rhabdomyolysis , and CLINICAL PHARMACOLOGY, Pharmacokinetics .) Interactions With Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone The risk of myopathy is also increased by the following lipid-lowering drugs that are not strong CYP3A4 inhibitors, but which can cause myopathy when given alone. See WARNINGS , Myopathy/Rhabdomyolysis. Gemfibrozil Other fibrates Niacin (nicotinic acid) (≥1 g/day) Other drug interactions Cyclosporine: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine (see WARNINGS , Myopathy/Rhabdomyolysis ).

Source: FDA prescribing information (DailyMed). Set ID: 9438d8a0-ca5b-4676-aab9-d0241ccff6c9. SPL document ID: 574beb60-70f7-dfa0-e063-6394a90aa90d. Label effective date: July 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.